David Kim to United States
This is a "connection" page, showing publications David Kim has written about United States.
Connection Strength
0.942
-
Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending. JAMA Netw Open. 2022 Nov 01; 5(11):e2243449.
Score: 0.091
-
State-Level Variation In Low-Value Care For Commercially Insured And Medicare Advantage Populations. Health Aff (Millwood). 2022 09; 41(9):1281-1290.
Score: 0.090
-
Effect of the 2012 US Preventive Services Task Force Recommendations on Prostate-Specific Antigen Screening in a Medicare Advantage Population. Med Care. 2022 12 01; 60(12):888-894.
Score: 0.090
-
How Does Cost-Effectiveness Analysis Inform Health Care Decisions? AMA J Ethics. 2021 08 01; 23(8):E639-647.
Score: 0.084
-
Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence? Value Health. 2021 11; 24(11):1586-1591.
Score: 0.083
-
An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 11; 36(11):3448-3455.
Score: 0.081
-
Crisis into opportunity: can COVID-19 help set a path to improved health care efficiency? Am J Manag Care. 2020 09; 26(9):369-370.
Score: 0.079
-
Cost Effectiveness of Nutrition Policies on Processed Meat: Implications for Cancer Burden in the U.S. Am J Prev Med. 2019 11; 57(5):e143-e152.
Score: 0.074
-
The influence of time horizon on results of cost-effectiveness analyses. Expert Rev Pharmacoecon Outcomes Res. 2017 Dec; 17(6):615-623.
Score: 0.063
-
Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis. Value Health. 2016 Jul-Aug; 19(5):602-13.
Score: 0.058
-
Health and Economic Impacts of Implementing Produce Prescription Programs for Diabetes in the United States: A Microsimulation Study. J Am Heart Assoc. 2023 08; 12(15):e029215.
Score: 0.024
-
What is the cost-effectiveness of menu calorie labelling on reducing obesity-associated cancer burdens? An economic evaluation of a federal policy intervention among 235 million adults in the USA. BMJ Open. 2023 04 18; 13(4):e063614.
Score: 0.024
-
Medicare Part D Coverage of Antiobesity Medications - Challenges and Uncertainty Ahead. N Engl J Med. 2023 Mar 16; 388(11):961-963.
Score: 0.023
-
Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022 07 12; 80(2):138-151.
Score: 0.022
-
Cost-effectiveness Analysis of Nutrition Facts Added-Sugar Labeling and Obesity-Associated Cancer Rates in the US. JAMA Netw Open. 2021 04 01; 4(4):e217501.
Score: 0.020
-
Variation in US private health plans' coverage of orphan drugs. Am J Manag Care. 2019 10; 25(10):508-512.
Score: 0.018
-
Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Med. 2018 09; 7(9):4251-4260.
Score: 0.017